Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369265 | 0.79 | RAB9A (0.64) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL784574 | 0.77 | RAB9A (1.00) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30583066 | 0.77 | RAB9A (1.00) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL15063517 | 0.77 | RAB9A (0.69) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10048497 | 0.77 | MAPT (0.97) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL26113669 | 0.76 | RAB9A (0.69) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL30902074 | 0.76 | RAB9A (0.69) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL230157 | 0.75 | POLB (0.84) | RAB9ANPC1MAPTGAADDAH1 | |
| SCHEMBL29822900 | 0.75 | SMN1; SMN2 (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL27681975 | 0.75 | SMN1; SMN2 (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540332-B2 | Benzimidazole derivatives as selective blockers of persistent sodium current | ALLERGAN, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160355485-A9 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ORGANIC SOLUTIONS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20150011591-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLERGAN INC (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2809656-A2 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLERGAN, INC. (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8859780-B2 | Benzimidazole derivatives as selective blockers of persistent sodium current | ALLERGAN, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859780-B2 | Benzimidazole derivatives as selective blockers of persistent sodium current | ALLERGAN, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859780-B2 | Benzimidazole derivatives as selective blockers of persistent sodium current | ALLERGAN, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130172389-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLEGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172389-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLEGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172389-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLEGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013101911-A2 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013101911-A2 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011591-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | SCN1B, CACNA1E, SCN2B | RAB9A 1550/4885NPC1 768/4885MAPT 2318/4885 |
| US-20130172389-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | SCN1B, CACNA1E, SCN2B | RAB9A 1550/4885NPC1 768/4885MAPT 2318/4885 |
| US-20160355485-A9 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | SCN1B, CACNA1E, SCN2B | RAB9A 1550/4885NPC1 768/4885MAPT 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.